| Literature DB >> 26460720 |
Martina Džambová1, Zuzana Sečníková1, Anna Jiráková1, Kateřina Jůzlová1, Ondřej Viklický2, Lenka Hošková3, Dana Göpfertovà4, Jana Hercogová1.
Abstract
Malignant melanoma is considered to be an immunogenic tumor, which is expected to change its behaviour in the field of immunosuppression. Although the incidence of melanoma in organ transplant recipients is increased to a smaller degree than in non-melanoma skin cancer, its potential morbidity and mortality has to be considered in the posttransplant care. The aim of this review is to investigate the relationship between melanoma and immunosuppression and to discuss management strategies for different melanoma scenarios in pre-transplant as well as posttransplant period.Entities:
Keywords: immunosuppression; malignant melanoma; prognosis; therapy
Mesh:
Substances:
Year: 2015 PMID: 26460720 DOI: 10.1111/dth.12276
Source DB: PubMed Journal: Dermatol Ther ISSN: 1396-0296 Impact factor: 2.851